Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors

30 Oct 2020

Abstract excerpt

A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1) antibody remains to be explored. We assessed 46 patients with advanced gastric cancer who received PD-1 antibody immunotherapy and 425-genes next-generation sequencing (NGS) testing. Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Cholangiocarcinoma and Gallbladder Cancer Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33126883
DOI: 10.1186/s12943-020-01274-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitorsPMID 33126883Read ↗

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity Read ↗

Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.Semantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma.Semantic proximity Read ↗

Clinical applications and perspectives of circulating tumor DNA in gastric cancerSemantic proximity Read ↗

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.Semantic proximity Read ↗

Clinical significance of circulating plasma DNA in gastric cancerSemantic proximity Read ↗

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Semantic proximity Read ↗

Liquid Biopsy in Gastric Cancer: Analysis of Somatic Cancer Tissue Mutations in Plasma Cell-Free DNA for Predicting Disease State and Patient Survival.Semantic proximity Read ↗

Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer.Semantic proximity Read ↗

Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach AdenocarcinomaSemantic proximity Read ↗

[Application of next-generation sequencing technology detecting ctDNA in the diagnosis and treatment of gastric cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.